Recently men with advanced prostate cancer have found that their insurance companies have been dictating what drugs they can get instead of their doctor making the best decision for them. At Malecare we have seen that when a man with metastatic castrate resistant prostate cancer (mCRPC) has finished taking chemotherapy they have been steered by some of their insurance companies to take Zytiga before Xtandi (Zytiga is a cheaper drug than Xtandi.) Both of these drugs are equally effective for these men, but their mechanism of action is entirely different.
In reality the only similarities between Zytiga and Xtandi are that both drugs are approved for use with men who have castrate resistant prostate cancer and who have had prior chemotherapy with any taxane based therapy like Taxotere (docetaxel) or Jevtana (cabazitaxel). Currently, Zytiga is also approved for use with a man who is castrate resistant and has not had any chemotherapy (there are ongoing trials designed to obtain a similar approval for Xtandi.)
Xtandi is an androgen rec